Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes
Achieves primary endpoint with statistically significant reduction in A1C versus placebo Excellent safety profile Conference call today at 8:30 a.m. ET to review Phase IIb data; Extended review event and conference call scheduled for November 18th NEW YORK, November 12, 2019 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused […]
